The use of TPE, where the patient’s plasma is filtered and replaced with a 5–20% albumin solution, was investigated for its effectiveness to mitigate the progression of mild-to-moderate Alzheimer’s disease. Here, ALB is linked to early-onset autosomal dominant Alzheimer disease.